Avacincaptad Pegol
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dry Age-Related Macular Degeneration
Conditions
Dry Age-Related Macular Degeneration
Trial Timeline
Jul 16, 2009 → Mar 24, 2011
NCT ID
NCT00950638About Avacincaptad Pegol
Avacincaptad Pegol is a phase 1 stage product being developed by Astellas Pharma for Dry Age-Related Macular Degeneration. The current trial status is completed. This product is registered under clinical trial identifier NCT00950638. Target conditions include Dry Age-Related Macular Degeneration.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06970665 | Approved | Recruiting |
| NCT05536297 | Phase 3 | Completed |
| NCT02686658 | Phase 2/3 | Completed |
| NCT02397954 | Phase 2 | Completed |
| NCT00950638 | Phase 1 | Completed |
| NCT00709527 | Phase 1 | Completed |
Competing Products
20 competing products in Dry Age-Related Macular Degeneration